Drug Profile
Entolimod - Statera BioPharma
Alternative Names: CBLB-502; CYTO-601; CYTO-601 ARS; CYTO-602; CYTO-602 Oncology; STAT-600; STAT-601Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cleveland BioLabs
- Developer Statera BioPharma
- Class Anti-ischaemics; Antidotes; Antineoplastics; Chemoprotectants; Peptides; Radioprotectives; Recombinant proteins
- Mechanism of Action Apoptosis inhibitors; NF-kappa B modulators; Toll-like receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Acute radiation syndrome
- Preclinical Radiation injuries
- No development reported Reperfusion injury; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Russia (IM, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IM, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (SC, Injection)